567
Participants
Start Date
June 29, 2015
Primary Completion Date
December 11, 2017
Study Completion Date
March 13, 2019
F/TAF
200/10 mg FDC tablet (with boosted 3rd ARV agents) or 200/25 mg FDC tablet (with unboosted 3rd ARV agents) administered orally once daily
ABC/3TC
600/300 mg FDC tablets administered orally once daily
ABC/3TC Placebo
Tablets administered orally once daily
F/TAF Placebo
Tablets administered orally once daily
3rd ARV agent
An allowed 3rd ARV agent of the participant's pre-existing regimen may include one of the following boosted ARV agents: ritonavir boosted lopinavir (LPV/r), atazanavir (ATV) + ritonavir (RTV), ATV + cobicistat (COBI) or ATV/COBI FDC, darunavir (DRV) + RTV, DRV+COBI or DRV/COBI FDC; or, one of the following unboosted ARV agents: efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP).
Spectrum Medical Group, Phoenix
Pacific Oaks Medical Group, Beverly Hills
University of California San Diego (UCSD), La Jolla
Anthony Mills, MD, Inc., Los Angeles
Peter J. Ruane, MD, Inc., Los Angeles
Highland Hospital - Alameda Health System, Oakland
La Playa Medical Group and Clinical Research, San Diego
Capial Medical Associates, Washington D.C.
Dupont Circle Physician's Group, Washington D.C.
Whitman-Walker Health, Washington D.C.
Gary J. Richmond,M.D.,P.A., Fort Lauderdale
Therafirst Medical Center, Fort Lauderdale
Midway Immunology and Research Center, Ft. Pierce
Orlando Immunology Center, Orlando
Triple O Research Institute PA, West Palm Beach
Atlanta ID Group, Atlanta
Howard Brown Health Center, Chicago
University of Louisville, Louisville
LSU Health Sciences Center, New Orleans
Be Well Medical Center, Berkley
Hennepin County Medical Center, Minneapolis
The KC CARE Clinic, Kansas City
Southampton Healthcare, Inc., St Louis
Saint Michael's Medical Center, Newark
South Jersey Infectious Disease, Somers Point
Southwest CARE Center, Santa Fe
Montefiore Medical Center, The Bronx
Philadelphia FIGHT, Philadelphia
Central Texas Clinical Research, Austin
AIDS Arms, Inc, Dallas
Tarrant County Infectious Disease Associates, Fort Worth
Gordon E. Crofoot MD PA, Houston
Therapeutic Concepts, PA, Houston
Peter Shalit, MD, Seattle
UZ Gent, Ghent
Centre Hospitalier Universitaire CHU Sart Tilman Liege, Liège
Clinique medicale l'Actuel, Montreal
Maple Leaf Research, Toronto
Spectrum Health, Vancouver
Vancouver ID Research and Care Centre Society, Vancouver
Hvidovre Hospital, Copenhagen
CHU - Groupe Saint-Andre, Bordeaux
CHU de Bordeaux, Bordeaux
C.H.U. de Nantes, Nantes
CHR Orleans la Source, Orléans
Chu Tours, Tours
ICH Study Center Hamburg, Bielefeld
Medizinische Universitatsklinik, Bonn
Klinikum der Universitaet Koln, Cologne
Universitatsklinikum Essen, Essen
Johann Wolfgang Goethe-University Hospital, Frankfurt
ifi-Studien und Projekte GmbH an der Asklepiosklinik St. Georg, Hamburg
Universitatsklinikum Hamburg-Eppendorf, Hamburg
Universitätsklinikum München, Munich
Mater Misericordiae University Hospital, Dublin
Saint James's Hospital, Dublin
University of Brescia, Brescia
Azienda Ospedaliera Luigi Sacco, Milan
Fondazione IRCCS San Raffaele del Monte Tabor, Milan
Azienda Ospedaliero Universitaria Policlinico di Modena, Modena
Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma
Ospedale Amedeo di Savoia - Specializzato Malattie infettive, Torino
Clinical Research Puerto Rico, San Juan
Hope Clinical Research Inc, San Juan
Bonaventura, Badalona
Hospital Universitari de Bellvitge, Barcelona
Hospital Vall d'Hebron, Barcelona
Hospital Clínico Universitario San Carlos, Madrid
Hospital General Universitario Gregorio Maranon, Madrid
Hospital Costa Del Sol, Málaga
Karolinska University Hospital, Stockholm
Birmingham Heartlands Hospital, Birmingham
Barts Health NHS Trust, London
Chelsea and Westminster Hospital, London
Imperial College, London
Kings College Hospital NHS Trust, London
Lewisham and Greenwich NHS Trust, London
Royal Free Hospital, London
St. George's Hospital, London
Manchester Centre for Sexual Health, Manchester
Lead Sponsor
Gilead Sciences
INDUSTRY